Skip to main content
Premium Trial:

Request an Annual Quote

GeneLogic Moves into Agricultural Genomics, Acquires Oncormed

Premium

GAITHERSBURG, Md.--Gene Logic has announced a partnership with Hoechst Schering AgrEvo GmbH to develop novel crop protection and improvement products. A genomics company that has until now applied its products to human genome research, GeneLogic will construct an agricultural research database using its proprietary gene expression and bioinformatics technologies. Research and database fees paid by AgrEvo during the three-year term of the agreement could reach over $45 million, GeneLogic predicted. AgrEvo will also gain access to GeneLogic's proprietary Flow-Thru Chip technology for further analysis of genes identified in the research program.

GeneLogic also announced that it will acquire all outstanding Oncormed stock in a transaction valued at not more than $38 million. The combined company resulting from the merger will be a subsidiary of Gene Logic, based in Gene Logic's facility here. Gene Logic said Oncormed's proprietary technologies, resources, clinical experience, and portfolio of pharmacogenomics alliances will enable the combined companies to support aspects of drug discovery and development, including target identification and validation, the discovery of new drug leads, and clinical trials.

Filed under

The Scan

Missed Early Cases

A retrospective analysis of blood samples suggests early SARS-CoV-2 infections may have been missed in the US, the New York Times reports.

Limited Journal Editor Diversity

A survey finds low diversity among scientific and medical journal editors, according to The Scientist.

How Much of a Threat?

Science writes that need for a provision aimed at shoring up genomic data security within a new US bill is being questioned.

PNAS Papers on Historic Helicobacter Spread, Brain Development, C. difficile RNAs

In PNAS this week: Helicobacter genetic diversity gives insight into human migrations, gene expression patterns of brain development, and more.